LU92701I2 - Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive - Google Patents

Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive Download PDF

Info

Publication number: LU92701I2
Authority: LU; Luxembourg
Prior art keywords: pasireotide; hydrate; leads; occur; pharmaceutically acceptable
Prior art date: 2003-11-14

Application number

LU92701C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-14

Filing date

2015-04-29

Publication date

2015-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34593737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92701(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-14 Priority claimed from GB0326602A external-priority patent/GB0326602D0/en

2004-03-19 Priority claimed from GB0406241A external-priority patent/GB0406241D0/en

2015-04-29 Application filed by Novartis Ag filed Critical Novartis Ag

2015-11-02 Publication of LU92701I2 publication Critical patent/LU92701I2/fr

Links

VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 title 1
229960005415 pasireotide Drugs 0.000 title 1
108700017947 pasireotide Proteins 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)

LU92701C 2003-11-14 2015-04-29 Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive LU92701I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0326602A GB0326602D0 (en)	2003-11-14	2003-11-14	Organic compounds
GB0406241A GB0406241D0 (en)	2004-03-19	2004-03-19	Organic compounds
PCT/EP2004/012870 WO2005046645A1 (fr)	2003-11-14	2004-11-12	Composition pharmaceutique

Publications (1)

Publication Number	Publication Date
LU92701I2 true LU92701I2 (fr)	2015-11-02

Family

ID=34593737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92701C LU92701I2 (fr)	2003-11-14	2015-04-29	Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive

Country Status (30)

Country	Link
US (3)	US7759308B2 (fr)
EP (1)	EP1686964B9 (fr)
JP (1)	JP4682145B2 (fr)
KR (1)	KR101233892B1 (fr)
AR (1)	AR047310A1 (fr)
AT (1)	ATE455537T1 (fr)
AU (1)	AU2004289055C1 (fr)
BR (1)	BRPI0416227B8 (fr)
CA (1)	CA2541944C (fr)
CY (2)	CY1110293T1 (fr)
DE (1)	DE602004025271D1 (fr)
DK (1)	DK1686964T3 (fr)
EC (1)	ECSP066565A (fr)
ES (1)	ES2339026T3 (fr)
HR (1)	HRP20100190T1 (fr)
IL (1)	IL175286A (fr)
IS (1)	IS8480A (fr)
LU (1)	LU92701I2 (fr)
MA (1)	MA28155A1 (fr)
MX (1)	MXPA06005357A (fr)
MY (1)	MY158342A (fr)
NO (2)	NO337172B1 (fr)
NZ (1)	NZ546788A (fr)
PE (1)	PE20050581A1 (fr)
PL (1)	PL1686964T3 (fr)
PT (1)	PT1686964E (fr)
RU (1)	RU2404749C2 (fr)
SI (1)	SI1686964T1 (fr)
TW (1)	TWI295178B (fr)
WO (1)	WO2005046645A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY158342A (en) *	2003-11-14	2016-09-30	Novartis Ag	Pharmaceutical composition
KR20130024988A (ko) *	2005-12-22	2013-03-08	노파르티스 아게	옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100816065B1 (ko) *	2006-11-27	2008-03-24	동국제약 주식회사	초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
CN101677952B (zh) *	2007-05-18	2012-12-05	杜雷科特公司	改进的贮库制剂
PE20090387A1 (es)	2007-05-24	2009-04-28	Novartis Ag	Formulacion de pasireotida
CA2713339C (fr) *	2008-01-30	2017-01-17	Novartis Ag	Preparation a liberation soutenue comprenant de l'octreotide et trois polymeres lineaires polylactide-co-glycolide
AU2009232000B2 (en)	2008-04-03	2014-12-11	Baxter International Inc.	Hemostatic microspheres
US9314508B2 (en)	2008-07-08	2016-04-19	Novartis Ag	Use of somatostatin analogs in control of hypoglycemia
AR074603A1 (es) *	2008-12-15	2011-01-26	Novartis Ag	Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
US8815971B2 (en)	2008-12-22	2014-08-26	ATRP Solutions, Inc.	Control over controlled radical polymerization processes
US8822610B2 (en)	2008-12-22	2014-09-02	ATRP Solutions, Inc.	Control over controlled radical polymerization processes
US8173750B2 (en)	2009-04-23	2012-05-08	ATRP Solutions, Inc.	Star macromolecules for personal and home care
WO2010123574A1 (fr)	2009-04-23	2010-10-28	Atrp Solutions Inc	Macromolécules en étoile pour soins d'hygiène personnelle et soins domestiques
US9783628B2 (en)	2009-04-23	2017-10-10	ATRP Solutions, Inc.	Dual-mechanism thickening agents for hydraulic fracturing fluids
US9587064B2 (en)	2010-12-08	2017-03-07	ATRP Solutions, Inc.	Salt-tolerant star macromolecules
WO2013131879A1 (fr)	2012-03-07	2013-09-12	Novartis Ag	Nouvelle application pour la pasireotide
EP2890760A4 (fr)	2012-08-30	2016-10-12	Atrp Solutions Inc	Agents épaississants à double mécanisme pour des fluides de fracturation hydraulique
EP2951220B1 (fr)	2013-02-04	2020-11-25	Pilot Polymer Technologies, Inc.	Macromolécules en étoile tolérantes aux sels
WO2014164754A1 (fr)	2013-03-11	2014-10-09	Durect Corporation	Composition injectable à libération contrôlée comprenant un véhicule liquide à haute viscosité
TW201605488A (zh) *	2013-10-15	2016-02-16	大塚製藥股份有限公司	用以預防及／或治療多囊腎病之藥物
MX385886B (es)	2014-07-03	2025-03-18	Pilot Polymer Tech Inc	Macromoleculas estrellas compatibles con tensoactivos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU221294B1 (en)	1989-07-07	2002-09-28	Novartis Ag	Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en)	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
MY147327A (en)	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
WO1998032423A1 (fr)	1997-01-29	1998-07-30	Takeda Chemical Industries, Ltd.	Microspheres a liberation prolongee, leur production et utilisation
WO2000004916A1 (fr) *	1998-07-23	2000-02-03	Societe De Conseils De Recherches Et D'applications Scientifiques Sas	Encapsulation de peptides hydrosolubles
EP1240896A3 (fr) *	1998-07-23	2003-03-26	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Encapsulation de peptides hydrosolubles
AU4964699A (en) *	1998-07-23	2000-02-14	Biomeasure Incorporated	Encapsulation of water soluble peptides
JP4303438B2 (ja)	1999-08-18	2009-07-29	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	ペプチドの持続放出製剤
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds
JP4679822B2 (ja) *	2002-03-13	2011-05-11	ノバルティスアーゲー	医薬微粒子
MY158342A (en) *	2003-11-14	2016-09-30	Novartis Ag	Pharmaceutical composition

2004
- 2004-11-09 MY MYPI20044662A patent/MY158342A/en unknown
- 2004-11-11 AR ARP040104157A patent/AR047310A1/es not_active Application Discontinuation
- 2004-11-12 NZ NZ546788A patent/NZ546788A/en not_active IP Right Cessation
- 2004-11-12 HR HR20100190T patent/HRP20100190T1/hr unknown
- 2004-11-12 TW TW093134728A patent/TWI295178B/zh active
- 2004-11-12 EP EP04797866A patent/EP1686964B9/fr not_active Expired - Lifetime
- 2004-11-12 ES ES04797866T patent/ES2339026T3/es not_active Expired - Lifetime
- 2004-11-12 KR KR1020067009270A patent/KR101233892B1/ko not_active Expired - Lifetime
- 2004-11-12 US US10/579,186 patent/US7759308B2/en active Active
- 2004-11-12 PE PE2004001111A patent/PE20050581A1/es active IP Right Grant
- 2004-11-12 RU RU2006120484/15A patent/RU2404749C2/ru active
- 2004-11-12 CA CA2541944A patent/CA2541944C/fr not_active Expired - Lifetime
- 2004-11-12 PL PL04797866T patent/PL1686964T3/pl unknown
- 2004-11-12 WO PCT/EP2004/012870 patent/WO2005046645A1/fr not_active Ceased
- 2004-11-12 DE DE602004025271T patent/DE602004025271D1/de not_active Expired - Lifetime
- 2004-11-12 AT AT04797866T patent/ATE455537T1/de active
- 2004-11-12 MX MXPA06005357A patent/MXPA06005357A/es active IP Right Grant
- 2004-11-12 BR BRPI0416227A patent/BRPI0416227B8/pt not_active IP Right Cessation
- 2004-11-12 DK DK04797866.3T patent/DK1686964T3/da active
- 2004-11-12 PT PT04797866T patent/PT1686964E/pt unknown
- 2004-11-12 JP JP2006538808A patent/JP4682145B2/ja not_active Expired - Lifetime
- 2004-11-12 SI SI200431378T patent/SI1686964T1/sl unknown
- 2004-11-12 AU AU2004289055A patent/AU2004289055C1/en active Active
2006
- 2006-04-27 IL IL175286A patent/IL175286A/en active IP Right Grant
- 2006-05-11 MA MA29019A patent/MA28155A1/fr unknown
- 2006-05-12 EC EC2006006565A patent/ECSP066565A/es unknown
- 2006-05-23 IS IS8480A patent/IS8480A/is unknown
- 2006-06-14 NO NO20062777A patent/NO337172B1/no active Protection Beyond IP Right Term
2010
- 2010-03-09 CY CY20101100222T patent/CY1110293T1/el unknown
- 2010-06-08 US US12/796,132 patent/US8188037B2/en not_active Expired - Lifetime
2012
- 2012-04-26 US US13/456,681 patent/US20120214749A1/en not_active Abandoned
2015
- 2015-03-26 CY CY2015011C patent/CY2015011I2/el unknown
- 2015-04-29 LU LU92701C patent/LU92701I2/fr unknown
2016
- 2016-02-02 NO NO2016003C patent/NO2016003I1/no unknown

Also Published As

Publication number	Publication date
CA2541944A1 (fr)	2005-05-26
RU2404749C2 (ru)	2010-11-27
BRPI0416227B1 (pt)	2019-06-18
EP1686964B9 (fr)	2010-08-04
US20100272809A1 (en)	2010-10-28
US8188037B2 (en)	2012-05-29
CY1110293T1 (el)	2015-01-14
US7759308B2 (en)	2010-07-20
ES2339026T3 (es)	2010-05-14
AU2004289055B2 (en)	2008-10-30
PT1686964E (pt)	2010-02-04
ECSP066565A (es)	2006-10-17
MXPA06005357A (es)	2006-07-10
DE602004025271D1 (de)	2010-03-11
CY2015011I1 (el)	2016-04-13
NO20062777L (no)	2006-08-14
JP4682145B2 (ja)	2011-05-11
PL1686964T3 (pl)	2010-06-30
IS8480A (is)	2006-05-23
KR20060115873A (ko)	2006-11-10
TWI295178B (en)	2008-04-01
JP2007511482A (ja)	2007-05-10
IL175286A (en)	2012-05-31
ATE455537T1 (de)	2010-02-15
KR101233892B1 (ko)	2013-02-18
NO2016003I2 (no)	2016-02-02
BRPI0416227B8 (pt)	2021-05-25
EP1686964A1 (fr)	2006-08-09
HK1093682A1 (en)	2007-03-09
TW200529883A (en)	2005-09-16
BRPI0416227A (pt)	2007-01-02
PE20050581A1 (es)	2005-09-09
US20120214749A1 (en)	2012-08-23
WO2005046645A1 (fr)	2005-05-26
DK1686964T3 (da)	2010-05-17
CY2015011I2 (el)	2016-04-13
AR047310A1 (es)	2006-01-18
AU2004289055C1 (en)	2009-05-21
NO337172B1 (no)	2016-02-01
NZ546788A (en)	2009-12-24
SI1686964T1 (sl)	2010-05-31
AU2004289055A1 (en)	2005-05-26
HRP20100190T1 (hr)	2010-06-30
IL175286A0 (en)	2006-09-05
EP1686964B1 (fr)	2010-01-20
NO2016003I1 (no)	2016-02-02
CA2541944C (fr)	2014-02-25
MY158342A (en)	2016-09-30
MA28155A1 (fr)	2006-09-01
RU2006120484A (ru)	2007-12-27
US20070212418A1 (en)	2007-09-13

Publication	Publication Date	Title
LU92684I2 (fr)	2015-11-02	Fidaxomicine ou son sel pharmaceutiquement acceptable
LU92702I2 (fr)	2016-07-29	Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
LU92883I2 (fr)	2016-01-20	Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
LU92678I2 (fr)	2015-11-02	Tobramycine ou un sel pharmaceutiquement acceptable qui en dérive
NO2016003I2 (no)	2016-02-02	Pasireotid eller et farmasøytisk akseptabelt salt derav eller et hvilket som helst hydrat derav
DK1704324T3 (da)	2013-02-18	Leddelt falsk havbund
DE50307359D1 (de)	2007-07-12	Mehrdecksiebmaschine
EP1773116A4 (fr)	2011-11-16	Systeme d'aquaculture en mer
DE60317391D1 (de)	2007-12-27	Verbinder
DE60301239D1 (de)	2005-09-15	Verbinder
DE60335913D1 (de)	2011-03-10	Ghrelin-analoga
NO20042118L (no)	2004-12-06	Halvt neddykkbar offshoreplattform
DE60315937D1 (de)	2007-10-11	Verbinder
DE60208885D1 (de)	2006-04-13	Verbinder
DE60330377D1 (de)	2010-01-14	Giessgefäss
NO20020265L (no)	2003-07-18	Fortöyningsanordning
DE60223352D1 (de)	2007-12-20	Verbinder
AP2004003156A0 (en)	2004-12-31	Peptide deformylase inhibitors.
ITMI20022022A1 (it)	2004-03-25	Analoghi di nocicettina.
NO20033825D0 (no)	2003-08-28	Styrt brönnhodeböye
DE10301279B8 (de)	2008-07-10	Verbinder
DE60218623D1 (de)	2007-04-19	Verbinder
ITTO20020045A0 (it)	2002-01-16	Giubbotto per immersione.
DE60312105D1 (de)	2007-04-12	Verbinder
GB0218955D0 (en)	2002-09-25	Avian sex determination method